For decades, living in Germany could disqualify you from donating blood in countries like the United States, Canada, and Australia. The reason was mad cow disease, or more precisely, the fear that people exposed to contaminated beef in Europe might silently carry a related human brain disease called variant Creutzfeldt-Jakob disease (vCJD) and pass it along through a blood transfusion. Many of those restrictions have been significantly relaxed or removed in recent years, but whether you can donate today depends on which country’s blood service you are approaching, how long you lived in Germany, and when.
Why Living in Germany Ever Mattered
The story starts with bovine spongiform encephalopathy, commonly known as BSE or mad cow disease. The United Kingdom experienced a massive BSE epidemic through the 1980s and 1990s, and the infectious agent, a misfolded protein called a prion, jumped to humans through contaminated beef. The human version, vCJD, is invariably fatal and has no cure. Germany was not the epicenter, but BSE cases were eventually confirmed in German cattle beginning in late 2000, prompting coordinated scientific investigation into prion diseases across the country.1Nature. Mad-cow outbreak spurs German drive to combat prion diseases Because prions can incubate silently for years or even decades before symptoms appear, blood services worldwide adopted a precautionary approach: if you had spent significant time in countries where BSE was present, you were deferred from donating.
In the United States, the FDA implemented geographic deferral criteria that affected millions of people, including military families stationed at bases in Germany, civilian expatriates, students who studied abroad, and anyone who had traveled extensively in Europe during the risk period. The deferral thresholds varied by country and time frame, but for much of Europe, spending a cumulative five or more years on the continent between 1980 and 2001 was enough to be turned away. For people who had lived in the UK specifically, the threshold was even shorter. These rules removed a substantial number of otherwise healthy donors from the eligible pool.
Can Prions Actually Spread Through Blood?
The deferral was not hypothetical caution. Research confirmed that prion diseases can be transmitted by blood transfusion, even when the donor shows no symptoms whatsoever. Animal studies using sheep infected with BSE demonstrated that all major blood components, including red blood cells, platelets, and plasma, were capable of transmitting prion disease when donors were still in the preclinical phase of infection.2PLoS Pathogens. Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection Earlier work had already shown that positive transmissions occurred with blood taken at both preclinical and clinical stages, confirming the real-world risks and lending support to the UK’s decision to restrict blood use.3Journal of General Virology. Transmission of prion diseases by blood transfusion
In humans, the concern played out exactly as feared. In the UK, four cases of vCJD were linked to blood transfusions from donors who later developed the disease. Those cases cemented what the animal research had suggested and made blood services around the world more cautious. The problem is compounded by a diagnostic gap: there is no approved large-scale screening test that can detect prion infection in a blood donor. Without such a test, it is impossible to know how many people in the donor population might be silently infected.4Transfusion. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France That absence of a screening tool is a key reason the geographic deferral approach lasted as long as it did. When you cannot test for something, the next best option is to exclude people who had the highest chance of exposure.
How the Rules Have Changed
The peak of BSE in Europe is now more than two decades in the past, and the number of new vCJD cases worldwide has dropped to near zero. This prompted a reassessment of whether the geographic deferrals were still proportionate to the actual risk, especially as chronic blood shortages became a growing concern. The FDA developed a risk-ranking model to calculate the geographic vCJD risk based on country-specific case rates and person-years of exposure among US blood donors.5Transfusion. Geographic exposure risk of variant Creutzfeldt‐Jakob disease in US blood donors: a risk‐ranking model to evaluate alternative donor‐deferral policies That modeling work contributed to a significant policy shift. In 2020, the FDA revised its guidance, removing many of the European travel and residence deferrals that had been in place for roughly two decades. Under the updated policy, spending time in Germany during the BSE risk period is no longer an automatic disqualification for donating blood in the United States.
The impact of lifting these deferrals has been measurable. In one large blood service that implemented the policy change, about 13% of newly surveyed first-time donors turned out to be newly eligible, and roughly 8% of donors who had previously been deferred for vCJD risk returned to donate.6PubMed Central. Removal of deferrals for variant Creutzfeldt-Jakob disease risk: Impact on new and previously deferred donors The return rate was highest among people who had been deferred most recently, which makes sense: someone told five years ago that they could not donate is more likely to try again than someone turned away in 2002 who may have long since given up.
Other countries have followed a similar trajectory, though the timing and specifics vary. Canada, Australia, and several European nations have all revisited their BSE-related deferral criteria. If you were previously told you could not donate because of time spent in Germany, the answer today may well be different. The best step is to check directly with your local blood collection organization, since policies can differ not just by country but by individual blood service.
What If You Want to Donate While Living in Germany?
If you are currently living in Germany and want to donate there, the BSE-related geographic deferral is not your concern. Germany’s own blood services do not defer donors simply for having lived in Germany. Instead, the German system uses a detailed donor questionnaire designed to identify health and travel risks that might affect either the safety of the blood supply or the donor’s own well-being.7Karger. Selecting the Right Donors – Still a Challenge: Development of a Uniform Donor Questionnaire in Germany The questionnaire covers recent illnesses, medications, sexual history, tattoos, piercings, and travel to regions where certain infections are endemic.
Germany’s eligibility rules for blood donation are broadly similar to those in other Western European countries. You need to be in good health, within an acceptable age range, and meet minimum weight and hemoglobin thresholds. Some deferrals are temporary, like waiting a set period after certain vaccinations, dental procedures, or minor infections. Others are longer-term, related to conditions like autoimmune disorders or a history of certain cancers. The rules are updated periodically as the risk landscape changes.
Travel-Related Deferrals Beyond Mad Cow Disease
Even if the vCJD deferral no longer applies to you, other travel-related restrictions might. Blood services worldwide screen for risks tied to where donors have recently been, and Germany’s location in central Europe introduces a few considerations that catch some donors by surprise.
West Nile virus is the most prominent example. The virus has been spreading northward through Europe, and Germany recorded its first locally acquired human infections in recent years. Under EU directives, donors who have visited an area with ongoing West Nile virus transmission must be deferred for 28 days unless they test negative on an individual molecular test.8Transfusion Medicine and Hemotherapy. West Nile Virus in Germany: An Emerging Infection and Its Relevance for Transfusion Safety This mostly affects donations during the late summer and early autumn mosquito season, and the specific regions considered at risk can change from year to year. A broader European perspective on this issue shows that noncompliance with donor deferral or testing requirements could result in infected blood components entering the supply from traveling donors exposed in outbreak areas.9Vox Sanguinis. West Nile virus and blood transfusion safety: A European perspective
West Nile virus is not the only arboviral concern for European blood safety. Tick-borne encephalitis virus has already been found in reservoir hosts in England, and the first locally acquired human cases have been documented there. Dengue virus and Usutu virus are also considered emerging threats to blood safety in the UK and Northern Europe.10Transfusion Medicine. A blood safety perspective on emerging arboviral infections in the United Kingdom While these are more immediately relevant to the UK blood supply, the underlying pattern applies across Northern Europe: the list of infections that blood services need to worry about is growing, not shrinking, and travel within Europe can trigger temporary deferrals you would not have encountered a decade ago.
Hepatitis E is another less obvious concern. Asymptomatic hepatitis E infections have been found in blood donors across several European countries, including Germany.11Eurosurveillance. Hepatitis E in blood donors: investigation of the natural course of asymptomatic infection, Germany, 2011 Most healthy people clear the virus without ever knowing they had it, but for immunocompromised recipients, a transfusion-transmitted hepatitis E infection can be serious. Some blood services now screen for hepatitis E; others rely on donor questioning and post-donation testing.
If you have traveled to malaria-endemic regions, that triggers its own deferral period, typically several months to a year depending on the country’s rules. Germany itself is not a malaria risk area, but if your time in Germany included side trips to sub-Saharan Africa, South or Southeast Asia, or parts of Central and South America, those travels could affect your eligibility independently of where you were based.
Why There Is Still No Blood Test for Prions
The single biggest factor that kept the geographic deferrals in place for so long, and that still shapes how cautiously blood services approach the residual vCJD risk, is the absence of a practical screening test. Prions are not viruses or bacteria. They are misfolded versions of a normal protein, and detecting them in a blood sample at the extremely low concentrations present during the preclinical phase has proven extraordinarily difficult. Standard blood-bank screening catches HIV, hepatitis B, hepatitis C, syphilis, and several other agents using well-established molecular and antibody tests. Nothing comparable exists for prions at the scale needed to screen millions of donations per year.
Research into prion-specific blood tests has been ongoing for years, and some promising assays have emerged in laboratory settings. But the gap between a research-grade assay and a validated, high-throughput screening test suitable for a blood bank is enormous. Until that gap is closed, the fallback position remains a combination of donor selection and processing safeguards.
How Blood Processing Reduces Prion Risk
One of the key safeguards adopted during the BSE era is leukoreduction, the removal of white blood cells from donated blood. Prions in blood appear to be closely associated with white blood cells, so filtering them out substantially lowers the infectious load. Animal studies confirmed that leukoreduction resulted in significantly lower transmission rates for prion disease, though it did not completely prevent transmission from any blood component.2PLoS Pathogens. Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection Epidemiological data have supported these experimental findings, suggesting that the introduction of universal leukoreduction has had a positive impact on reducing vCJD transmission risk from blood products.12PubMed. Leukoreduction and blood-borne vCJD transmission risk
Beyond standard leukoreduction, researchers have developed specialized prion-reduction filters designed to remove the misfolded proteins more directly. One such filter, tested on red blood cell units spiked with prion material, achieved roughly a thousandfold reduction in infectivity.13Transfusion. Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion However, when prion-reduction filters were tested alongside standard leukodepletion filters in an animal transmission study, the additional benefit was less clear-cut. In one experiment, no clinical cases appeared in animals receiving blood filtered through a combined leukodepletion/prion-reduction device, but one apparently healthy recipient was still found to be infected at the end of the study, suggesting exposure to a low level of infectious material. The researchers noted that the small group sizes made it difficult to draw firm statistical conclusions about whether the prion-reduction filter added meaningful protection beyond what standard leukodepletion already provides.14PLoS ONE. Impact of Leucocyte Depletion and Prion Reduction Filters on TSE Blood Borne Transmission
In practice, universal leukoreduction is now standard in most developed countries, including Germany, the UK, the US, and Canada. It was introduced primarily for other clinical benefits, such as reducing febrile transfusion reactions and lowering the risk of certain viral transmissions, but the prion-reduction effect was an important secondary advantage. The specialized prion-removal filters have seen limited commercial adoption, partly because the residual vCJD risk is now considered extremely low and partly because the evidence for their additional benefit remains modest.
When a Previous Deferral Still Applies
Even with the broad relaxation of BSE-related deferrals, a few situations can still result in a deferral tied to European residence. In the United States, the FDA’s 2020 revised guidance removed the geographic deferral for most of Europe, but it retained a deferral for people who spent three months or more in the UK between 1980 and 1996, when the UK’s BSE exposure was at its peak. People who received a blood transfusion in the UK, France, or Ireland during specified risk years also remain deferred, because receiving blood in a country with documented transfusion-transmitted vCJD cases represents a more direct exposure pathway than simply living there.
If you lived exclusively in Germany and never received blood products in one of those higher-risk countries, the remaining US deferral is unlikely to apply to you. But the rules vary by blood service and can be updated, so it is always worth confirming with the specific organization where you plan to donate. The American Red Cross, for example, maintains an online eligibility tool where you can check your status before scheduling an appointment.
In other countries, the situation may be slightly different. Some nations lifted their European geographic deferrals earlier than the US; others may still maintain them in some form. Australia and Canada both revised their policies in recent years, but the fine print differs. If you have lived in multiple European countries, the interaction of different risk periods and thresholds can get complicated. The safest approach is to be upfront about your full travel and residence history and let the blood service’s screening process determine your eligibility.
Hepatitis E and the Changing European Risk Landscape
One aspect of donating blood in or after living in Germany that rarely makes headlines is hepatitis E. Unlike the dramatic BSE story, hepatitis E does not involve prions or decades-long incubation periods. It is a virus, and in Europe it spreads primarily through undercooked pork, wild game, and occasionally through contaminated water. Most infections in healthy adults are mild or completely asymptomatic, but for organ transplant recipients, people on immunosuppressive drugs, or those with pre-existing liver disease, a transfusion-transmitted hepatitis E infection can become chronic and dangerous.
Germany has one of the higher rates of hepatitis E exposure in Europe, likely reflecting dietary habits that include raw and undercooked pork products. Some German blood services have introduced screening for hepatitis E in donated blood, using molecular testing to catch donors who are actively shedding the virus without knowing it. This is a relatively recent development in transfusion medicine and not yet universally adopted across all blood services, even within Germany. The natural course of asymptomatic hepatitis E infection in donors is still an area of active study, and the optimal screening strategy is not yet settled.
For a prospective donor, hepatitis E screening is not something you need to worry about in terms of eligibility. You will not be deferred for having eaten raw sausage. But it is worth understanding that the safety measures built into modern blood banking extend well beyond the headline-grabbing concerns like HIV and BSE. A donation collected in Germany today goes through a battery of laboratory tests before it reaches a patient, and the list of things being tested for continues to grow as new threats are identified and as testing technology improves.